CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...
Phase 2
Valencia, Spain and 72 other locations
in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-low breast cancer with active brain metastases.This study will ana...
Phase 2
Valencia, Spain and 11 other locations
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer...
Phase 1
Valencia, Spain and 8 other locations
-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this stud...
Phase 3
Valencia, Spain and 52 other locations
the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any s ...
Valencia, Spain and 51 other locations
participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...
Phase 2
Valencia, Spain and 31 other locations
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Ca...
Phase 1
Valencia, Spain and 16 other locations
number of mutations per coding area of a tumor genome). The HER2-E and Basal-like profiles have been associated with high mutational burden ...
Phase 2
Valencia, Spain and 14 other locations
of T- VEC combined with Atezolizumab in women with operable early breast cancer who present residual disease after Neoadjuvant Chem...
Early Phase 1
Valencia, Spain and 3 other locations
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast...
Phase 2
Valencia, Spain and 43 other locations
Clinical trials
Research sites
Resources
Legal